Insider buying last 90 days
No open-market insider purchases were filed for KNSA in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every KNSA insider filing, plotted on the chart in Gekko.Open KNSA in Gekko
NASDAQ: KNSA
Kiniksa Pharmaceuticals International (KNSA) Stock Analysis & Forecast
Sep 28 close
$76.10+1.02 (+1.4%)
Gekko Brief
AI summaryThis week's coverage centers on analyst sentiment, with brokerages reiterating a consensus recommendation of "Moderate Buy" from ten ratings firms and a consensus price target of $87.38 cited for Kiniksa Pharmaceuticals International, plc.
KNSA closed at $76.10, up 1.4%, sitting just above both its 50-day average of $76.01 and its 200-day average of $55.53, with the shorter average above the longer one. The stock's one-year return stands at 114.3%, though the past month shows a decline of 4.6%. The GekkoIndex reads 58.3, placing the stock in the Neutral zone, up 1.8 over five days. Gekko Fair Value is set at $84.66, putting the current price 10.1% below that level.
Kiniksa's next earnings report is scheduled for 27 October 2026, before the open, falling within the next 20 trading days and marking the primary catalyst on the calendar. The prior quarter saw an EPS actual of $0.17 against an estimate of $0.35, with a 2.8% reaction, and the company has recorded 2 beats across the last 8 quarters, with an average absolute reaction of 8.2%. Seasonality over this stretch of the calendar has averaged a 1.8% gain across 5 years, rising in 3 of them. No insider, Congress, or unusual options activity appears in the current windows. Analyst coverage remains entirely positive, with 7 firms all rating the stock a buy and a consensus target of $98.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Kiniksa Pharmaceuticals International price vs fair value
Close $76.10200-day averageGekko Fair Value $84.66
Kiniksa Pharmaceuticals International quick facts
- Market cap
- $5.80B
- P/E ratio
- 76.9
- Forward P/E
- 59.5
- EPS, TTM
- $0.98
- Revenue, TTM
- $840.8M
- Profit margin
- 9.6%
- Dividend yield
- —
- Beta
- 0.09
- Volume
- 547,548 avg 499,852
- 1-year return
- +114.3%
- Typical daily move
- ±3.3%
- Typical 20-day move
- ±8%
- 50-day average
- $76.01
- 200-day average
- $55.53
- Next earnings
- Oct 27 before open
- Shares outstanding
- 46.30M
Kiniksa Pharmaceuticals International swing-trade checklist
Kiniksa Pharmaceuticals International scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendsupportive
Above 50 and 200-day
Close $76.10 is above the 50-day ($76.01) and 200-day ($55.53) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
58.3, Neutral
Reading 58.3 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
10.1% below
Price is 10.1% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 28 days
Reports on Oct 27, 2026, 28 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+1.8% on average
From this point in the calendar, the next 20 trading days averaged +1.8% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Kiniksa Pharmaceuticals International stock chart and price history
Kiniksa Pharmaceuticals International closed at $76.10 on Sep 28, 2026, +114.3% over the past year, inside a 52-week range of $35.20 to $82.94.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −4.6%
- 3 months
- +21.9%
- 6 months
- +66.3%
- 1 year
- +114.3%
The full KNSA chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open KNSA in Gekko
Follow Kiniksa Pharmaceuticals International through every session
Put KNSA on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track KNSA in GekkoFree for 7 days. No credit card required.
About Kiniksa Pharmaceuticals International
Kiniksa Pharmaceuticals International develops and sells medical treatments, working across the United States, the United Kingdom, and other countries. Its established product is ARCALYST, a cytokine-trapping therapy that targets interleukin-1alpha and 1beta and is used to treat recurrent pericarditis, an inflammatory heart condition, as well as cardiac sarcoidosis.
Beyond its marketed therapy, the company is advancing a pipeline of antibody-based candidates. KPL-387, a fully human monoclonal antibody, is being studied in a combined Phase 2/3 trial for recurrent pericarditis, while KPL-116, an Fc-modified monoclonal antibody, remains in earlier pre-clinical development. The company was previously called Kiniksa Pharmaceuticals, Ltd. before adopting its current name in June 2024.
Founded in 2015, Kiniksa Pharmaceuticals International is headquartered in London, United Kingdom. Its shares trade on the NASDAQ under the ticker KNSA.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- kiniksa.com
Kiniksa Pharmaceuticals International GekkoIndex: the smart money zone
Kiniksa Pharmaceuticals International’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 58.3, in the Neutral zone, up 1.8 points over five sessions.
58.3Neutral
Up 1.8 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 27 | +3.5% | +14.3% | ||
| Accumulation | 146 | +2.5% | +8.2% | ||
| Neutral (current zone) | 440 | +0.9% | +3.9% | ||
| Distribution | 55 | +0.3% | +1.5% | ||
| Selling | 4 | Too few readings yet | |||
Average KNSA share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the KNSA price, zone by zone.Track KNSA in Gekko
Is Kiniksa Pharmaceuticals International stock overvalued? Gekko Fair Value
Kiniksa Pharmaceuticals International trades 10.1% below Gekko Fair Value of $84.66, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Kiniksa Pharmaceuticals International shares are worth, recalculated every trading day.
$84.66
Gekko Fair Value, Sep 26, 2026
10.1% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open KNSA in Gekko
Kiniksa Pharmaceuticals International insider and Congress trading
No open-market insider purchases were filed for Kiniksa Pharmaceuticals International, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in KNSA were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for KNSA, plotted on the chart in Gekko.Open KNSA in Gekko
Buybacks
Kiniksa Pharmaceuticals International has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $316K
- As a share of market cap
- 0.01%
- Trailing four quarters
- $5.90M
From company filings.
Kiniksa Pharmaceuticals International earnings: next date and track record
Kiniksa Pharmaceuticals International reports on Oct 27, 2026, before the open (28 days away), and beat the EPS estimate in 2 of its last 8 reports.
Next earnings report
Oct 27, 2026
Expected before the open, 28 days away
- EPS estimate
- $0.39
- Revenue estimate
- $259.6M
2 of 8reports beat the EPS estimate
±8.2%average move across the report
6 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Mar 3, 2026 | $0.17 est $0.35 | — | +2.8% |
| Oct 28, 2025 | $0.23 est $0.32 | $180.9M est $197.1M | −7.9% |
| Jul 29, 2025 | $0.23 est $0.19 | $156.8M est $166.5M | +11.2% |
| Jun 5, 2025 | $0.11 est $0.28 | — | +4.7% |
| Feb 25, 2025 | −$0.12 est $0.02 | $122.5M est $123.4M | +0.3% |
| Oct 29, 2024 | −$0.18 est $0.01 | $112.2M est $123.4M | −16.6% |
| Jul 23, 2024 | −$0.06 est −$0.07 | $108.6M est $110.3M | +17.8% |
| Apr 23, 2024 | −$0.25 est −$0.16 | $79.86M est $78.46M | +4.4% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Kiniksa Pharmaceuticals International stock forecast and analyst price targets
Analysts’ average 12-month price target for Kiniksa Pharmaceuticals International is $98.00, +28.8% from the last close, from 7 firms rating the stock in the last 90 days.
$98.00consensus 12-month target, +28.8% from the last close
Now $76.10Avg $98.00
Low $87High $107
Each firm’s latest rating in the last 90 days: 7 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Jul 30 | Goldman Sachs | $90 | +18.3% |
| Jul 29 | J.P. Morgan | $107 | +40.6% |
| Jul 29 | Wells Fargo | $87 | +14.3% |
| Jul 29 | Citi | $100 | +31.4% |
| Jul 29 | Canaccord Genuity | $98 | +28.8% |
+3.9%average 20-day move after past Neutral readings
+1.8%average move over the next 20 trading days in the last 5 years
±3.3%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Kiniksa Pharmaceuticals International seasonality: the next 20 trading days
Over the next 20 trading days from Sep 26, Kiniksa Pharmaceuticals International averaged +1.8% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +2.4% | 3 of 5 |
| Next 10 trading days | +5.8% | 4 of 5 |
| Next 15 trading days | +4.6% | 3 of 5 |
| Next 20 trading days | +1.8% | 3 of 5 |
| Next 30 trading days | +11.6% | 3 of 5 |
For scale, KNSA’s typical 20-trading-day move in either direction is about 8%.
Kiniksa Pharmaceuticals International market cap and key statistics
Kiniksa Pharmaceuticals International’s market cap is $5.80B, with a P/E ratio of 76.9 and revenue of $840.8M over the last twelve months.
Valuation
- Market cap
- $5.80B
- P/E ratio
- 76.9
- Forward P/E
- 59.5
- EPS, TTM
- $0.98
- Gekko Fair Value
- $84.66
Trading
- Volume
- 547,548
- Avg volume, 20 days
- 499,852
- 52-week high
- $82.94
- 52-week low
- $35.20
- Shares outstanding
- 46.30M
Financials
- Revenue, TTM
- $840.8M
- Profit margin
- 9.6%
- Return on equity
- 14%
- Quarterly earnings growth, YoY
- +30.4%
Risk and income
- Beta
- 0.09
- Typical daily move
- ±3.3%
- Typical 20-day move
- ±8%
Kiniksa Pharmaceuticals International stock news this week
1 headline about Kiniksa Pharmaceuticals International from the past week, newest first, each linking to the publisher.
Kiniksa Pharmaceuticals International peers
Kiniksa Pharmaceuticals International’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 17.9% above |
| JNJJohnson & Johnson | Neutral | 0.5% above |
| ABBVAbbVie | Neutral | 23.3% above |
| MRKMerck | Neutral | 4.2% below |
| AZNAstraZeneca | Neutral | 39.9% below |
| PFEPfizer | Neutral | 4.0% below |
A peer links to its own page where one exists.
Kiniksa Pharmaceuticals International stock FAQ
What is Kiniksa Pharmaceuticals International’s market cap?
Kiniksa Pharmaceuticals International’s market cap is $5.80B at the Sep 28, 2026 close of $76.10, with 46.30M shares outstanding. The shares trade on a P/E ratio of 76.9.
What is the Kiniksa Pharmaceuticals International stock forecast?
The consensus analyst 12-month price target for Kiniksa Pharmaceuticals International is $98.00, +28.8% from the last close. Of the 7 firms that rated the stock in the last 90 days, 7 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Kiniksa Pharmaceuticals International stock overvalued or undervalued?
On Gekko’s estimate Kiniksa Pharmaceuticals International is undervalued: the Sep 28, 2026 close of $76.10 is 10.1% below Gekko Fair Value of $84.66. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Kiniksa Pharmaceuticals International report earnings next?
Kiniksa Pharmaceuticals International is expected to report on Oct 27, 2026, before the market opens (28 days away). Analysts expect earnings of $0.39 per share on revenue of $259.6M. Kiniksa Pharmaceuticals International beat the earnings estimate in 2 of its last 8 reports, moving 8.2% on average across the report.
What is Kiniksa Pharmaceuticals International’s 52-week high and low?
Kiniksa Pharmaceuticals International’s 52-week high is $82.94 and its 52-week low is $35.20; it closed at $76.10 on Sep 28, 2026, +114.3% over the past year.
Is Kiniksa Pharmaceuticals International stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (trend, fair value and seasonality), 1 as mixed (gekkoindex) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Kiniksa Pharmaceuticals International the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.